(OTCBB: CNSJ), (Pink Sheets: RQST), (NASDAQ: VLNC), (Nasdaq: HOTT).

Turning Pennies into dollars: (OTCBB: CNSJ), (Pink Sheets: RQST), (NASDAQ: VLNC), (Nasdaq: HOTT).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://cnsj.realpennies.com

China Shuangji Cement Ltd. (OTCBB: CNSj) (February 5, 2008) announced a corporate update and an action plan for this quarter.

"The change to our corporate name and ticker symbol on November 9, 2007 marks a new direction for the Company," said China Shuangji Chairman and President Wenji Song.

China Shuangji expects to receive the audited financial statements of Shandong Zhaoyuan Shuangji Group Co., Ltd. ("SZSG") and contemplates filing the necessary Form 8-K with the Securities and Exchange Commission on a series of contractual agreements with SZSG, a domestic company registered in the People's Republic of China which is engaged in the business of manufacturing of cement products.

Mr. Song further stated, "I believe that each company has undeveloped endless potential. Looking ahead, our Company faces valuable developmental opportunities, along with many difficulties and challenges. We will execute the development strategies already approved, on the basis of the strengthening cement industry, to implement brand name effectiveness, and to expand in both the domestic and international markets. Our focus will be on leveraging the Company's strengths and stepping up business development, in order to provide the best products to our customers and as well to make Shuangji a large-scale international corporation. The Company is in the new historic development stage.

We will continue to do what is necessary to establish strong corporate governance, in order to protect the interests of the Company and all shareholders. With the support of all our shareholders, and the combined efforts of the Board of Directors, management and staff, I firmly believe that Shuangji is blessed with a very promising future."

For more info: http://rqst.realpennies.com

Royal Acquisitions and Development, Inc. (Pink Sheets: RQST) (February 7, 2008) has consulted numerous top senior geologists in an effort to better evaluate their concession. The search has been exhausting, and has been narrowed down to three leading firms. As per company policy, Royal Acquisitions and Development, Inc. will commence the final tendering process for said contract.

The sampling methods, sample shipment, preparation, and data entry will follow the established, stringent guidelines of international exploration under the supervision of a Qualified Person / Senior Geologist, and meet the guidelines for 43-101 Standards of Disclosure for Mineral Projects report requirements

Royal Acquisitions and Development, Inc. C.E.O., Richard Cartagena stated the following, "We are aggressively moving forward on our business plan, and the hiring of a top senior geologist lends further credibility to our concession plus allows us to proceed on the development of our concession. We feel 2008 has been a good year to start but there is tireless work ahead, our team is committed."

Our Concession

The RQST land claim lies wholly in Sahuaripa County, Sonora, Mexico. According to el Imparcial (the predominate regional newspaper of Sonora), the gold production in Sahuaripa County alone will be roughly 4.65 tons of gold this year. As an example, the Mulatos mine provided in the first quarter of 2006 22,680 ounces of gold, the Dolores mine reported in the first quarter of 2006 3,000,000 ounces of gold and 149,000,000 ounces of silver, and the El Sauzal mine has recorded gold reserves of nearly 2,000,000 ounces.

Further, the upward trend in neighboring mining reporting data, lends sufficiency to the preliminary RQST assays. The RQST property neighbors such rich mining sites as Mulatos of Alamos Gold (TSX.AGI) to the North, Dolores of Minefinders (TSX.MFL) to the East, and El Sauzal of Glamis Gold/Goldcorp (TSX.G) to the South and lends credence and raises expectations that the RQST property has enormous potential that at least meets the proven reserves of these well documented neighboring gold mines.

For more info: http://cnsj.realpennies.com

Valence Technology, Inc. (NASDAQ: VLNC) (February 7, 2008) announced it has entered into a contract with The Tanfield Group Plc (LSE: TAN) to manufacture and supply safe, Lithium Phosphate energy storage systems to power zero emission, all-electric commercial delivery vehicles. The Valence battery systems will be installed in leading-edge vans and trucks produced by Tanfield's UK-based trading division, Smith Electric Vehicles, the world's largest manufacturer of electric vans and trucks.

Under the agreement, Tanfield will purchase up to $70 million of Valence products in the contract's first phase and Valence has already received a firm purchase order for the first calendar quarter.

The agreement will also result in Tanfield becoming the first volume customer for Valence's third generation Lithium Phosphate Epoch technology, a battery system equipped with an advanced management system that monitors and automatically adjusts cell performance so battery packs operate at their optimum performance capacity. Epoch benefits include a fail-soft capability that is designed to eliminate system failure caused by a single cell and to have a life cycle comprised of more than 2000 charge cycles when deep discharged in demanding electric vehicle applications.

"The Valence Epoch System which we introduced at the December 2007 EVS-23 show has the potential to move the industry closer to the tipping point when EVs and plug-in HEVs will be broadly adopted and deployed," said Robert L. Kanode, president and CEO of Valence. "We believe that Valence is the first Lithium Phosphate battery producer to have the sourcing and manufacturing capability and start-to-finish infrastructure to immediately ship safe, reliable, Lithium Phosphate energy storage systems in the quantities demanded by the electric vehicle market. For the past six months we have been working to scale up our proven operational capabilities to meet anticipated demand."

Darren Kell, Chief Executive of The Tanfield Group Plc, said "We are constantly looking for new, cost-effective technologies that can improve our zero emission commercial electric vehicles and broaden our customer base. The Valence battery pack is an efficient, inherently robust and reliable system that gives us greatly increased flexibility in vehicle design."

Tanfield launched the first of its new generation of Smith zero-emission commercial vehicles in December 2006 and has quickly developed a wide customer portfolio across the UK and mainland Europe, including Sainsbury's Online, the Royal Mail, TNT Express, Carlsberg, Balfour Beatty, Amey Construction and DHL Exel Supply Chain.

Smith launched its first United States-specific vehicle at EVS-23 in California in December 2007.

For more info: http://hott.realpennies.com

Hot Topic, Inc. (Nasdaq: HOTT ) (February 6, 2008) announced the sales results for its fiscal month of January as well as its fourth quarter and fiscal year (four weeks, thirteen weeks and fifty-two weeks, respectively, ended February 2, 2008). A summary of the sales results by division (including internet) is as follows:

Net Sales (1)

------------------------

% Change

$ to Last Comparable Store

Millions Year Sales % Change (2)

---------- ---------- -------------------

JANUARY:

Hot Topic $ 32.4 -27.4% -4.4%

Torrid $ 8.8 -6.1% 0.8%

Total Co. $ 41.2 -23.7% -3.6%

FOURTH QUARTER:

Hot Topic $183.3 -11.4% -7.2%

Torrid $ 37.2 10.5% -0.4%

Total Co. $220.5 -8.3% -6.3%

FISCAL YEAR:

Total Co. $728.0 -3.1% -4.4%

(1) Each of the current periods includes one less week as compared to last year. Fiscal 2007 was a 52-week year, compared to a 53-week year in fiscal 2006. The net sales % change to last year compares the current fiscal periods to last year's reported fiscal periods, ended February 3, 2007.

(2) Compares the current fiscal periods to the corresponding periods from the previous fiscal year.

The company also announced that it has reduced the number of store projects planned for fiscal 2008 (52 weeks ending January 31, 2009). The company now expects to open approximately 10 Torrid stores during the year, 15 to 20 less than previously announced. In addition, the company now expects to remodel or relocate 25 Hot Topic stores during the year, 5 less than previously announced. Based upon the reduced number of store projects, the company now expects capital expenditures for the full year of fiscal 2008 to be in the range of $24 to $26 million. The company previously issued guidance for fiscal 2008 capital expenditures in the range of $28 to $30 million.

The company reiterated its fourth quarter earnings guidance of $0.25 to $0.29 per diluted share, compared to fourth quarter earnings of $0.20 per diluted share last year.

For more detailed information relating to the above matters, please call 626-709-1209 to listen to a recorded commentary.

Additionally, a conference call to discuss fourth quarter and fiscal year end results, business trends, guidance and other matters is scheduled for March 12, 2008 at 4:30 p.m. (ET). The live conference call number is 888-679-8034, pass code ''Hot Topic'', and will be accessible to all interested parties. It will also be webcast on the company's Investor Relations website at http://investorrelations.hottopic.com. Participants who would like to pre-register for the conference call may do so by accessing the company's Event Calendar on the Investor Relations website and using the pass code 46886742 (or the numeric touchtone spelling of ''Hot Topic''). A replay of the conference call will be available at 888-286-8010, pass code 19194201, for approximately two weeks. In addition, a webcast replay of the conference call will be available on the company's Investor Relations website.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com

(OTCBB: CNSJ), (OTCBB: CYOE), (OTCBB: PPBV), (Nasdaq: IDMI).

Turning Pennies into dollars: (OTCBB: CNSJ), (OTCBB: CYOE), (OTCBB: PPBV), (Nasdaq: IDMI).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://cnsj.realpennies.com

China Shuangji Cement Ltd. (OTCBB: CNSJ) (February 5, 2008) announced a corporate update and an action plan for this quarter.

"The change to our corporate name and ticker symbol on November 9, 2007 marks a new direction for the Company," said China Shuangji Chairman and President Wenji Song.

China Shuangji expects to receive the audited financial statements of Shandong Zhaoyuan Shuangji Group Co., Ltd. ("SZSG") and contemplates filing the necessary Form 8-K with the Securities and Exchange Commission on a series of contractual agreements with SZSG, a domestic company registered in the People's Republic of China which is engaged in the business of manufacturing of cement products.

Mr. Song further stated, "I believe that each company has undeveloped endless potential. Looking ahead, our Company faces valuable developmental opportunities, along with many difficulties and challenges. We will execute the development strategies already approved, on the basis of the strengthening cement industry, to implement brand name effectiveness, and to expand in both the domestic and international markets. Our focus will be on leveraging the Company's strengths and stepping up business development, in order to provide the best products to our customers and as well to make Shuangji a large-scale international corporation. The Company is in the new historic development stage.

We will continue to do what is necessary to establish strong corporate governance, in order to protect the interests of the Company and all shareholders. With the support of all our shareholders, and the combined efforts of the Board of Directors, management and staff, I firmly believe that Shuangji is blessed with a very promising future."

For more info: http://cyoe.realpennies.com

CytoCore Inc. (OTCBB: CYOE) (February 5, 2008), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, announced today that the U.S. Food and Drug Administration has approved the company's 510(k) submission to sell CytoCore's SoftPAP cervical cell collector. The SoftPAP collects more comprehensive and complete cervical cell specimens for Pap testing.

"CytoCore's SoftPAP cervical cell collector is a significant advance in women's health," says Robert McCullough, Jr., CytoCore's CEO. "Each year, over 2 million American women are told that their Pap test was negative when, in fact, they have early stage cervical cancer. These false negatives are frequently caused by an inadequate or incomplete sample of cervical cells. SoftPAP collects complete specimens from the cervical canal, the cervical surface and the transition zone simultaneously. There is evidence that the use of SoftPAP significantly reduces the rate of false negative Pap tests leading to earlier treatment of cervical cancer."

"Studies also demonstrate that the most common adverse events that occur during the collection of the specimen are virtually eliminated with the SoftPAP," according to Dr. Richard Domanik, President and COO. "Studies involving more than 400 cervical cell collections show a 95% reduction in bleeding and spotting which are the most frequently reported adverse events associated with collection of specimens for Pap testing."

"FDA clearance enables us to become a truly global company," says Dan McMahon, Director of Marketing. "We have been selling SoftPAP in Europe for the past few months and are negotiating distribution agreements in Latin America as well. We are in the final stages of completing the North American distribution organization and expect to be able to launch the product in the United States by the end of the first quarter."

For more info: http://ppbv.realpennies.com

Purple Beverage Company, Inc. (OTCBB: PPBV) (February 4, 2008) announced that it has been chosen by Morgan & Sampson as a new entry in its roster of well-known, well-respected household brands. Morgan & Sampson USA is a multi-faceted consumer product broker whose territory encompasses the entire United States.

Backed by an 87-year history of growth and service, Morgan & Sampson USA (M&S USA) represents a wide array of products ranging from pharmaceutical items to consumables. With nine offices nationwide and an additional office in the UK, M&S USA services some of the largest chains in the country, including well-known store giants Kroger, Safeway, Albertson's, Costco, Longs Drugs and many more national retailers. M&S USA's selection of products includes such household names as Kleenex , Sunbeam , Rival , Bremner-Ralston , RyKrisp Crackers and Remington , and for these and other quality goods, M&S USA develops and implements retail placement strategies that maximize sales and economic returns for both the product manufacturer and the retailers.

"We are thrilled to be partnering with Morgan & Sampson USA as part of our national rollout strategy. They are undoubtedly one of the best and most respected consumer brand product brokers in the country," said Ted Farnsworth, Founder and CEO of Purple Beverage Company. "Along with their expertise in representing well-known brands that have been around for years, they have also been instrumental in launching new brands to the marketplace that soon become household names - a fact that excites us greatly. Although Purple has been available in select stores nationwide since the product launched in 2007, our goal has always been to bring this all-natural, healthy and fun beverage to consumers everywhere. Teaming with M&S USA means that Purple will now be as close to many consumers as the shelves of their neighborhood grocery store."

Chip Carter, Chief Executive Officer for Morgan and Sampson USA, added, "After watching Purple gain exceptional traction in the marketplace in such a short period of time, we are extremely excited to add a beverage of Purple's quality to our lineup. With the growing demand for all-natural, functional beverage alternatives, we are confident that the market is ripe for an enthusiastic Purple reception." For more information about Morgan and Sampson USA, visit www.morgansampsonusa.com/.

Purple is a unique and invigorating blend of seven of the world's most powerful antioxidant juices, including the exotic acai berry, black cherry, pomegranate, black currant, purple plum, cranberry and blueberry. Combined, these juices result in an all-natural, no-sugar added beverage that is perfect as a stand-alone drink or as part of a healthy fruit smoothie.

Purple is also quickly becoming one of the most trendy antioxidant cocktail choices in nightclubs and lounges where available, as adding alcohol to antioxidant-rich berries increases the potency of the antioxidants, a fact confirmed by researchers from the United States Department of Agriculture and by a study at Kasetsart University in Thailand.

Since debuting in select cities coast to coast in 2007, Purple has been praised by such high-profile publications as Health Magazine and Family Circle.

Purple can be found in health food stores, restaurants, delis, drug stores, supermarkets and convenience stores in select locations, including New York, Los Angeles, Miami and Hawaii. In February, it became available in select GNC stores, and look for it nationwide in early 2008. For more information, visit www.drinkpurple.com.

For more info: http://idmi.realpennies.com

IDM Pharma, Inc. (Nasdaq: IDMI) (February 4,2008) on Monday announced the Journal of Clinical Oncology (JCO) has published findings from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133), entitled "Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report from the Children's Oncology Group." The landmark clinical trial, which is the largest study completed in this disease was a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG).

The COG's findings were based on long-term follow up of 662 patients with newly diagnosed non-metastatic osteosarcoma treated in the Phase 3 trial and demonstrated that the addition of L-MTP-PE to chemotherapy following surgery resulted in statistically superior Overall Survival (OS) the first stated aim of the study.

In the past two decades, there have been no treatment advances for patients with osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.

"L-MTP-PE in combination with chemotherapy has demonstrated a significant long-term overall survival advantage in the largest Phase 3 clinical trial completed in patients with osteosarcoma," said Dr. Paul Meyers, vice chair, department of pediatrics at Memorial Sloan-Kettering Cancer Center and principal investigator of the Phase 3 trial. "These results are encouraging for children and young adults with osteosarcoma, considering the lack of progress for these patients in the last 20 years."

The JCO publication highlighting long-term follow up from this study formed the basis of the recent oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), regarding the Marketing Authorization Application (MAA) for L-MTP-PE for the treatment of patients with non-metastatic, resectable osteosarcoma. Updated results from this study were previously presented at the Connective Tissue Oncology Society (CTOS) annual meeting in November 2007. In addition, the new JCO publication highlights the long-term OS data whereas a prior JCO publication in 2005 focused on an Event Free Survival (EFS) additional analysis.

"These findings of statistically superior overall survival in long-term patient follow-up validate the survival benefit offered by L-MTP-PE and underscore the desperate need for new treatments for osteosarcoma patients," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We believe these findings were critical to the recent opinion from the Committee for Medicinal Products for Human Use in Europe and are a positive step toward bringing this important treatment to the European market and potentially gaining approval in the United States."

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com